TrippBio is developing a patent-pending repurposed FDA-approved drug called TD213.
TD213 is administered orally twice daily and works by blocking replication of the SARS-CoV-2 virus and the associated acute inflammatory response to the infection.
TrippBio is founded on the scientific research of Ralph Tripp, Ph.D., Georgia Research Alliance chair and professor at the University of Georgia.
The study was conducted by Dr. Moti N. Ramgopal of Midway Immunology and Research Center.
Outpatients who tested positive using a validated SARS-CoV-2 RNA COVID-19 test were given TD213 twice daily for 14 days and will be followed through day 28.
After 14 days, 90% of enrolled patients receiving TD213 had cleared the virus. Dr. Ramgopal, the principal investigator, said, "I was very pleased to see that 20% of the patients cleared by day five, and 40% by day ten, as well as the 14-day clearance data.
Especially, when compared to the median time of 17.2 days to stop viral shedding reported in a mild-moderate population in a recently published review of 77 studies looking at COVID-19 patients.
An initial review of laboratory tests showed that a critical marker of inflammation, high-sensitive C-reactive protein (hsCRP), improved after four days of treatment in 60% of patients and 90% of patients after 14 days of treatment.
TrippBio believes that TD213 is a viral modulator and potentially an important treatment for mild to moderate COVID-19 infections.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007